| |||||||||||||||||||||||||||||||||||||||||
Joseph
Coyle, Chair During the 2003 President's Plenary Session the ACNP announced a full complement of honorific awards. The Daniel H. Efron Award is presented to an individual who has made outstanding basic research contributions to Neuropsychopharmacology. This year's winner was David Bredt, M.D., Ph.D., University of California, San Francisco. David Bredt has expanded the boundaries of neurotransmitter characteristics through his path-breaking findings of the diffusible signaling molecule, nitric oxide, and how glutamatergic AMPA receptors are regulated.
The Joel Elkes Award for outstanding clinical contributions to psychopharmacology was awarded to Husseini Manji, M.D., National Institute of Mental Health. Husseini Manji provides a stellar example of translational research in psychiatric disorders as he has probed basic mechanisms of the elusive action of mood stabilizers and tested these hypotheses in clinical studies.
The Paul Hoch Distinguished Service Award was given this year to Thomas A. Ban, M.D., an active contributor to the Archives project and an emeritus member of the ACNP History Committee. Tom Ban is a much-loved ACNP member who has given tirelessly of his time and energy to document the history of the College as well as the field of Neuropsychopharmacology.
The second annual ACNP Media Award, recognizing a journalist who has made an important contribution to neuropsychopharmacology by educating the general public, was awarded to Tim McCann. Mr. McCann wrote and directed an independent film called Revolution #9. This film accurately and honestly portrays schizophrenia and its symptoms, highlights the impediments to care posed by the illness and our systems of care, and stresses the important role that medication plays in the treatment of serious mental illness.
Council approved
a recommendation to establish a new honorific award, the Julius Axelrod
Mentorship Award. Julius Axelrod joined the ACNP in 1961 and is a Founding
Member of the College. He received the Nobel Prize for Physiology or Medicine
in 1970. In his illustrious career, he served as a mentor to many young
scientists who later became distinguished researchers in their own right. This Award
may be presented annually to an ACNP member who has made an outstanding
contribution to neuropsychopharmacology by mentoring and developing young
scientists into leaders in the field. The Award consists of a monetary
award and a plaque to be given during the President's Plenary Session.
The Award Winner must attend the Annual Meeting. This winner
of the Axelrod Mentorship Award will be selected from nominees submitted
to the Honorific Awards Committee. Any scientist may nominate an ACNP
member for this award by submitting the following to the Awards Committee: 1. A nominating
letter no more than three pages in length. This letter should describe
the contributions of the candidate to the people he/she has mentored. 2. A representative
list of people who have been mentored by the candidate, their job titles,
and the major contributions they have made to the field. 3. Letters
of support from no more than three people who have been mentored by the
candidate. These letters should provide specific information regarding
the contributions of the candidate to the person mentored. 4. The curriculum
vitae of the candidate.
New Deadlines and New Rules for Annual Meeting
Proposals and Abstracts Archival
Abstracts: Beginning
this year the ACNP Annual Meeting Abstracts will be published in a supplement
to Neuropsychopharmacology. Therefore, in order to allow the necessary
time for review of poster abstracts and to meet the publishers' deadlines,
all the due dates for submission of proposals and abstracts are earlier
this year. Posters:
The online site for submitting abstracts will open in May and the deadline
for Poster Abstracts will be Monday, August 16, 2004. Reminder: ACNP
Scientific members (excluding associate and administrative) may sponsor
ONE poster. A member may also present ONE poster. If a member does not
sponsor a poster, then he/she may present two posters. ACNP Scientific
members (excluding associate and administrative) only have ONE invitation
to the Annual Meeting. A poster presenter MUST be invited AND have an
ACNP member sponsor their poster. It does not have to be the same ACNP
member. If you agree to sponsor a poster, please remember to either invite
that individual to the meeting as your guest or advise him/her that you
already have invited someone else and he/she will need to secure an invitation
from another ACNP member. A member
may invite someone to the meeting even if the member is not attending
the meeting. Please send the invited guest's information to the ACNP in
writing. Panel
and Study Group Proposals: The call for proposals will be sent in
February. The proposals will be due in early May. Note: An ACNP member
must be the chair of the proposed session. In its December
meetings Council approved a new policy to help members stay fully informed
about Council actions. Minutes of Council meetings will be posted in the
Members Only area of the ACNP Website. To access this area of the Website
members must have established a user name and password. If you have not
yet done that you may call the Secretariat at (615) 322-2075 or e-mail
acnp@acnp.org, and a staff member will assist you. If you already have
your user name and password you may access the Council minutes by logging
on to the ACNP Website and then logging into the "Members Only"
area
Task Force on SSRI's and Suicide Issues a
Preliminary Report ACNP held
a briefing for news media, Capitol Hill staffers and mental health groups
on January 21, 2004 in Washington, DC to release the executive summary
of a preliminary ACNP task force report on SSRIs and suicidal behavior
in youth. J. John Mann, Graham Emslie, Joseph Coyle and Ellen Frank spoke
at the briefing. The event was well attended by members of the news media
and generated widespread news coverage including next-day stories in the
New York Times, USA Today, Wall Street Journal, Newsday, WebMD, and
Dallas Morning News. At the briefing,
members of the ACNP task force presented preliminary conclusions that
SSRI antidepressants do not increase the risk of suicidal thinking or
suicide attempts in youth and that several SSRIs have been shown to be
effective for treating depression in this population. The task force emphasized
that its findings and recommendations are preliminary, and noted that
although ACNP reviewed available data from clinical trials, epidemiology
and autopsy studies, it did not have access to a substantial amount of
data available to the FDA or to pharmaceutical companies. To view the
executive summary of the preliminary task force report click here.
Frankie
Trull The second
session of the 108th Congress began on January 20, 2004 and the first
order of business was completion of the FY2004 omnibus appropriations
bill that failed to pass the Senate in December. The Senate approved the
bill on January 22 by a vote of 65 to 28. The FY2004
omnibus spending measure includes a $1 billion increase (3.7%) for the
National Institutes of Health (NIH). Although this increase reflects the
higher Senate allocated number, it will be effectively reduced by: 1)
an across-the-board 0.59% reduction; 2) a provision requiring that 2.2%
of NIH's budget be used for program evaluations; and 3) a $150 million
transfer for the Global HIV/AIDS fund. After intensive lobbying by therapeutic
cloning advocates, including ACNP members, language to prevent the U.S.
Patent & Trademark Office (PTO) from issuing patents on human organisms
was ameliorated by accompanying report language stating the provision
would not interfere with stem cell research. Under the agreement, the
provision will ban patents for genetically engineered human embryos, fetuses
and human beings, but will not affect patents on genes, cells, tissue
and other biological products. In the State
of the Union speech, the president outlined his priorities for 2004. President
Bush reiterated his support for Social Security reform and called for
an end to "frivolous" medical malpractice lawsuits. While he
addressed the issue of health insurance, saying catastrophic health coverage
premiums should be deductible for those with a savings account program,
there was little mention of health research. Biomedical research advocates
have been concerned that increases to NIH will be minimal again this year.
Letters advocating an increase in the health care portion of the budget
have been sent to Congress and President Bush in advance of the release
of the budget next month. ACNP and over 230 organizations signed this
letter. NIH Conflict
of Interest Hearing Senator Arlen
Specter (R-PA) who chairs the Senate Appropriations Subcommittee on Labor,
HHS & Education, the subcommittee with jurisdiction over NIH funding,
held a hearing January 22 on "Avoiding Conflicts of Interest at the
National Institutes of Health." The hearing was initiated, in part,
as a result of allegations in a December article published in the Los
Angeles Times that senior NIH officials received millions of unreported
dollars in consulting contracts from pharmaceutical and biomedical companies
that had dealings with the agency. Sen. Specter announced in his opening
statement at the Senate hearing that while the issue of targeting specific
"controversial" grants for defunding remains a concern, this
hearing would focus on the recent reports of conflict of interest involving
NIH researchers. He continued his statement saying that among his concerns
is that with the significant increases NIH has received in the past, opponents
of future increases will point to this controversy. He said it is an issue
of integrity. In his testimony,
Dr. Zerhouni announced Bruce Alberts, Ph.D., president of the National
Academy of Sciences (NAS) and Norman R. Augustine, Chairman of the Executive
Committee of Lockheed Martin, would co-chair a new NIH Blue Ribbon Panel
on Conflict of Interest Policies. This panel, a working group of the Advisory
Committee to the Director, was established to review existing guidelines
for NIH scientists involved in external consulting. The committee
will wait for the panel's report before it makes any final decisions regarding
legislative changes, but it appears likely the rules at NIH regarding
conflict of interest and disclosure of consulting arrangements with outside
companies will be strengthened during this session of congress. Carol A.
Tamminga, M.D., UT Southwestern Medical School was awarded a Waterman
pen as the new signatory of the College during the ACNP business meeting
in San Juan on December 10, 2003. Dr. Tamminga outlined her priorities
for 2004, starting with her desire to emphasize pathophysiology in mental
illness. She also intends to work closely with the newly formed Public
Information Committee, chaired by Ellen Frank, as the ACNP expands its
efforts to provide important information and education to the media and
to the public. She plans to assign a Task Force to make recommendations
to Council about the future direction of the Journal, and acting upon
a Council recommendation she plans to appoint a group to work with Council
in a strategic planning session this year. Daniel R.
Weinberger, M.D., National Institute of Mental Health, assumed the role
of President-Elect. Stepping into their new roles as members of Council
were William T. Carpenter, Jr., M.D., Director, MPRC, University of Maryland
and Raquel E. Gur, M.D., Ph.D., Director, Neuropsychiatry, University
of Pennsylvania. Seated (left to right): Joseph Coyle, Dennis Charney, Charles
Nemeroff, Alan Schatzberg The College
elected 29 new members and 14 associate members during the 2003 Annual
Meeting. There were also 14 members who were promoted to fellow, 3 fellows
promoted to life fellow and two foreign corresponding fellows elected
to the College. Nicholas
Barden
A total of
46 travel awardees attended the 2003 ACNP Annual Meeting in San Juan,
Puerto Rico. This total included four Aventis Travel Awardees. Five NIMH
Minority Travel Awardees, twelve Bristol-Myers Squibb Travel Awardees,
nine ACNP Memorial Travel Awards, seven Travel Awardees from the APA Program
for Minority Research Training in Psychiatry, one GlaxoSmithKline Fellow,
one Pharmacia Minority Summer Fellow, three Anxiety Disorders Association
of America Travel Awardees, and four Eli Lilly Minority Faculty Awardees.
Susan
E. Swedo The Education
& Training Committee, in collaboration with the NIMH Intramural Research
Program, has arranged for the Eli Lilly travel awardees to receive formal
training in the writing of grant applications through the NIH grants-writing
course. The two-part course will be provided to the 2003 awardees: Yekeen
Aderibigbe (Morehouse School of Medicine), Tanya Alim (Howard University),
Letitia Pinson (Drew University) and Zia Wahid (Meharry Medical College.)
In the first session, the awardees will learn how to prepare a grant application
and will be encouraged to write an application for funding a training
award or research project. Their applications will then be reviewed and
"scored" at the second session. The grants-writing course will
meet the needs expressed by the young investigators to have more "protected"
research time. A successful grant application would allow them to pursue
an independent research project, or concentrate on research training.
The Eli Lilly
travel awardees also expressed interest in receiving formal training in
clinical neuroscience, as many are responsible for teaching a variety
of courses in neuropsychiatry. The ACNP Education and Training Committee
is committed to meeting this need, and is investigating the possibility
of offering a web-based course through the NIH Foundation for Advanced
Education in the Sciences. Ideally, a second course would be offered in
psychopharmacology, and both courses would be open to all ACNP travel
awardees.
|
Table of Contents
|
||||||||||||||||||||||||||||||||||||||||